Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)
Discontinued
Reference number: GID-TA10337
Following on from information provided to NICE by the company in December 2018, the appraisal of Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein [ID1362] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.